F-Spondin CRISPR Activation Plasmid (h): sc-404101-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- F-Spondin CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- F-Spondin CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by F-Spondin CRISPR Activation Plasmid (h) and F-Spondin CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SPON1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: F-Spondin Antibody (B-3): sc-390182
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
F-Spondin CRISPR Activation Plasmid (h) | sc-404101-ACT | 20 µg | $397.00 |
Human SPON1 encodes F-Spondin, a secreted extracellular matrix glycoprotein enriched in the nervous system that modulates neurite outgrowth, axon guidance, and synaptic organization. F-Spondin engages cell-surface receptors and matrix components to influence adhesion-dependent signaling and extracellular remodeling programs that shape neuronal connectivity. SPON1 expression is linked to developmental neurobiology and has been investigated in contexts of neurodegeneration and other disorders where synaptic integrity and matrix signaling are perturbed. In vitro, altering F-Spondin levels is commonly used to probe mechanisms of cell–matrix communication, neuronal differentiation, and microenvironment-dependent signaling.
F-Spondin CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SPON1 expression without altering the underlying DNA sequence.
F-Spondin CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SPON1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SPON1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous F-Spondin expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SPON1 locus and enabling the study of F-Spondin-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of F-Spondin pathway restoration in tumor cells with silenced or reduced SPON1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.